Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 880 | 80 | 794 |
| Samples | 785 | 69 | 710 |
| Peptides | 742 | 76 | 671 |
Function
ANKHD1-EIF4EBP3 · ANKHD1-EIF4EBP3 readthrough
The ANKHD1-EIF4EBP3 mRNA is an infrequent but naturally occurring readthrough transcript of the neighboring ANKHD1 and EIF4EBP3 genes. This readthrough transcript encodes a protein composed mostly of the multiple ankyrin repeats, single KH-domain protein, with its C-terminus encoded in a different reading frame from the shared portion of the EIF4EBP3 gene. The significance of this readthrough mRNA and the function of its protein product have not yet been determined. [provided by RefSeq, Nov 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000532219 | Q8IWZ3-6 | 880 | 742 |
Gene Properties
Recurrent Mutations
All 742 amino-acid changes on canonical ENST00000532219 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ANKHD1-EIF4EBP3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ANKHD1-EIF4EBP3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 46/612 8% |
| Melanoma | 7/210 3% | 90/1899 5% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Bladder Carcinoma | 1/58 2% | 34/956 4% |
| Cervical Carcinoma | 0/35 0% | 14/422 3% |
| Hodgkins Lymphoma | 1/16 6% | 3/122 2% |
| Colorectal Carcinoma | 8/143 6% | 88/3239 3% |
| Other Solid Cancers | 0/94 0% | 43/1515 3% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 34/1390 2% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 22/810 3% |
| Gastric Carcinoma | 1/74 1% | 39/1809 2% |
| Germ Cell Tumour | 1/25 4% | 3/169 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Hepatocellular Carcinoma | 0/46 0% | 46/2210 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 15/752 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 44/2550 2% |
| Non-Cancerous | 1/104 1% | 13/830 2% |
| Prostate Carcinoma | 0/13 0% | 27/2105 1% |
| Ovarian Carcinoma | 3/109 3% | 11/998 1% |
| Neuroendocrine Tumour | 4/154 3% | 5/577 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Head and Neck Carcinoma | 1/85 1% | 17/1574 1% |
| Other Sarcomas | 1/69 1% | 7/699 1% |
| Breast Carcinoma | 4/144 3% | 30/3264 1% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Glioma | 0/52 0% | 18/2127 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
Mutation Distribution
Where ANKHD1-EIF4EBP3 is mutated · all tissues, split by cell line vs tissue
How many mutations in ANKHD1-EIF4EBP3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 880 mutations in ANKHD1-EIF4EBP3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|